О РАСЧЛЕНЕИИ НИЖНЕКАМЕННОУΓОЛЫХ ОТЛОЖЕНИЙ СЕВЕРНОΓО СКЛОНА ХРЕБТА БОРО-ХОРО(ВОСТОЧНАЯ ЧАСТЬ ТЯНЬ-ШАНЯ,СИНЬЦЗЯНЬ)

B KoHue习X eT助eT“月PyeeKH盆reo月OrMy二KeToB H.B.(1575一1900r,r.)BnePB曰e Bhl八即朋HH水HeKaMeHH0yro几bHbleor卫咪eHu分no eo6PaHH滩‘HM中ayHePa3Pe30B H3BeCTH只KOBB BePx阳b只x P.A川a几a“P.八水ePra几aH eeBePHoroCKJIOHa玩Po·XoPo. flos及HeegTOTPa仑oH noceTM卫H HeMe双KHe reo卫orH:MeP玖6axeP(1907一1909r。r。Merzbaeher),rPe6eP(Gr6ber,1908一1909 r.r.),KPeHKe几b(KreDkel,1913 r.).OHHBflePBble八aJIH onHCaHHeOT几。尧KeHH直.BH3e直cKO直中ayH乒H TeM caM曰M yToq…     

Synthesis,characterization, and biological activity of Nα-(N-fluoresceinthiocarbamoyl)-(Asp1, Ile5)-angiotensin II

A fluorescent analog of angiotensin II was synthesized by reacting fluorescein 5′-isothiocyanate with (Asp¹, Ile⁵)-angiotensin II. N^α-(N-Fluoresceinthiocarbamoyl)-(Asp¹, Ile⁵)-angiotensin II was purified by chromatography on DEAE-cellulose and Sephadex G-25. Analysis of the analog by thin-layer chromatography, thin-layer electrophoresis, and reversed-phase high-performance liquid chromatography indicated that the analog was free of angiotensin II and fluorescein 5′-isothiocyanate. N-Terminal sequence analysis demonstrated that fluorescein 5′-isothiocyanate reacted with the N-terminal aspartic acid residue of angiotensin II. N^α-(N-Fluoresceinthiocarbamoyl)-(Asp¹, Ile⁵)-angiotensin II has an absorption maximum at 492 nm, and the value of the molar extinction coefficient, ?, is 7.7 × 10⁴m^?1 cm^?1. The fluorescence emission maximum occurs at 520 nm. Infusion of the analog (0.69 μg/min/kg body wt) directly into the renal artery of an anesthetized rat reduced the blood flow by 12 to 27% within 2 min. Infusion of angiotensin II (0.48 μg/min/kg body wt) reduced renal arterial blood flow by 35 to 53% within 2 min. Saralasin, a partial agonist and antagonist of angiotensin II, inhibited the biologic effect of the fluorescent analog and angiotensin II by 75 and 70%, respectively. The purity, spectral properties, and in vivo biologic activity of N^α-(N-fluoresceinthiocarbamoyl)-(Asp¹, Ile⁵)-angiotensin II indicate that this analog should facilitate characterization of angiotensin II receptors.     

(2R,3S,4S)-2-(N,N-二乙氨基)甲酰氧基-3-苯基-4-苯甲酰基-N-甲基-γ-内酰胺的合成及工艺研究

目的：通过对黄皮酰胺全合成中间体（2R,3S,4S）-2-羟基-3-苯基-4-苯甲酰基-N-甲基-γ-内酰胺（化合物A）2位羟基的酯化,提高脂水分配系数（kP）,考察对谷丙转氨酶活性的影响。方法：以化合物A为原料,通过酰化反应合成（2R,3S,4S）-2-（N,N-二乙氨基）甲酰氧基-3-苯基-4-苯甲酰基-N-甲基-γ-内酰胺（化合物B）,重点考察了摩尔比、反应温度、反应时间等条件对反应的影响。化合物B结构已经元素分析、红外光谱、质谱及核磁共振氢谱确证。结果：化合物A和酰化剂以摩尔比2：3,在160℃下反应1h,目标化合物B。收率78．42％。结论：本合成路线及具体反应方法,具有试剂廉价易得、反应条件温和、后处理简便等优点,是一种较为实用的合成方法。     

Definitive Solution Structures for the 6-Formylated Versions of 1-(βD-Ribofuranosyl)-, 1-(2′-Deoxy-β-D-Ribofuranosyl)-, and 1-β-D-Arabinofuranosyluracil,and of Thymidine

Abstract

ROESY and NOESY NMR spectroscopic analyses of the ribofuranosyl (1a), 2′-deoxyribofuranosyl (1b), and arabinofuranosyl (1c) derivatives of 6-formyluracil in (CD₃)₂SO and D₂O solutions have established that each exclusive 7,05′-cyclic hemiacetal diastereomer of 1a,b and the major 7,O2′-cyclic hemiacetal diastereomer of 1c possess the 7R configuration. In addition, (7R)-1c has been shown to be thermodynamically more stable than (7S)-1c, contrary to our previous indication. A new, higher yielding synthetic route to 1a has been developed, 1b has been obtained for the first time in crystalline form, the route to 1c has been modified to better accommodate large scale preparations, and a new, fourth member of this class, 6-formylthymidine (1d), has been synthesized and its solution structures in (CD₃)₂SO, D₂O, and CD₃OD have been determined. Antitumor and antiviral evaluations of 1a-c have revealed no significant levels of activity.